SK bioscience, a South Korea-based vaccine and biotech company, announced on Wednesday that it has signed a development licensing agreement with Hilleman Laboratories, a Singapore-based vaccines and biologics research and development company that said it is committed to improving vaccine accessibility and affordability for low- and middle-income countries.
The contract has been signed for joint development of a second-generation Zaire Ebola virus vaccine.
Hilleman Laboratories and SK bioscience will collaborate on the development of an improved second-generation Zaire Ebola virus vaccine candidate with the goal of increasing production process productivity and improving product thermostability that would potentially help increase the global Ebola vaccine supply and help expand access.
SK bioscience will acquire unique expertise and know-how for use of rVSV (recombinant Vesicular Stomatitis Virus Vector) technology platform, in close collaboration with Hilleman Laboratories with the potential to jointly develop other vaccines against a variety of viral infectious diseases.
Boehringer Ingelheim reports strong growth in 2023 and accelerates late-stage pipeline
AstraZeneca increases dividend by 7%
Poolbeg PHarma plc receives notice of allowance for POLB 001 patent
Wolters Kluwer enhances Clinical GenAI leadership with AI Labs powered by UpToDate
Amgen announces share dividend for Q2 2024
Virbac expands presence in Japan with Sasaeah acquisition
Bruker Corporation to acquire ELITechGroup for EUR870m, strengthening MDx portfolio
Danaher Corporation announces quarterly cash dividend
Abbott announces quarterly common dividend
Bruker expands Preclinical Imaging Portfolio with acquisition of Spectral Instruments Imaging
Fusion Antibodies announces receipt of follow-on project and provides R&D update
Alvotech reports positive results for AVT03, potential biosimilar to Prolia and Xgeva